November 17, 2026, 12pm-1pm ET
From the lab to the community: Familial Alzheimer’s disease in Jalisco, Mexico
Speakers: Dr. Angélica Zuno Reyes and Frida Rosales Leycegui
Autosomal dominant Alzheimer’s disease (ADAD) is a rare, inherited form of early- onset Alzheimer’s disease (AD) caused by nearly fully penetrant mutations, affecting families for generations. Because carriers of a causal mutation are born with a genetic alteration that virtually guarantees the onset of symptoms, often at a predictable age, ADAD offers a unique opportunity to study the disease before it manifests and throughout its stages, and to design preventive interventions for AD and related dementias. In Jalisco, Mexico, two large ADAD populations have been identified, carrying the PSEN1A431E (“Jalisco mutation”) or the APPV717I mutation.
This talk presents the work of a binational, multidisciplinary team at the Universidad de Guadalajara and the University of Southern California. Through an ongoing research protocol, the team has reconstructed historical pedigrees and conducted longitudinal functional, clinical, and cognitive assessments, as well as biosample collection, among other activities. Beyond the laboratory, we describe how community meetings and events, the development and implementation of genetic counseling programs, and social work and caregiving support have sustained long-term participant adherence, and how participants have become active partners in the research. Finally, we discuss future directions in neuroimaging, biomarkers, and clinical trials, and the role of community engagement in making ADAD research accessible and useful to the families it serves.
Please note that registration is required to attend. Click here to register.
December 15, 2026, 12pm-1pm ET
Genetic, pathologic and hormonal contributions to psychosis in Alzheimer’s disease
Speaker: Corinne Fischer
This presentation will examine putative mechanisms underlying psychosis in Alzheimer’s disease and how sex, APOE4 status and brain pathology may play a role. Specifically, we will examine how APOE4 status interacts with sex and pathology to determine psychotic phenotypes and how this knowledge may inform treatment. We will also examine the protective role of estrogen therapy in Alzheimer’s disease-related psychosis.
Please note that registration is required to attend. Click here to register.
Past webinars
What are you looking for?
Sleep for resilience: Translational insights from mouse models to human dementia
October 20, 2026
Culturally grounded, community-based, and self-determined dementia risk reduction research in Northwestern Ontario
September 22, 2026
The role of psychosocial, lifestyle, and health factors in cognitive and brain aging
May 19, 2026
“You have to be there”: Emotional labor, cultural ethics, and the realities of Black families of people with dementia in Canada during COVID-19
February 17, 2026
Caring for the family caregiver: Lived experiences of family caregivers and mindfulness-based interventions for older adult caregivers of persons with dementia
January 20, 2026
Developing Dementia Decoded: Acute Care Dementia Strategy at The Ottawa Hospital
December 16, 2025
Using plasma biomarkers to estimate the prevalence of Alzheimer’s Disease pathology in COMPASS-ND
November 17, 2025
Use of lecanemab and donanemab in the Canadian healthcare system: Evidence, challenges, and areas for future research
May 20, 2025
The content of this webinar is based on this scientific review paper: Smith E. et al. (2025), Use of Lecanemab and Donanemab in the Canadian Healthcare System: Evidence, Challenges, and Areas for Future Research. Journal of Prevention of Alzheimer’s Disease.
Visit this page for frequently asked questions about the use of new medications for Alzheimer’s disease in the Canadian healthcare system
Dementia-related apathy: Recent advances in diagnosis and treatment
April 29, 2025
This presentation is based on this scientific review paper: Lanctôt K.L. et al. (2023) Distinguishing apathy from depression: A review differentiating the behavioral, neuroanatomic, and treatment-related aspects of apathy from depression in neurocognitive disorders. International Journal of Geriatric Psychiatry. Feb., 38(2):e5882.
Consult this page for an infographic tool for clinicians on distinguishing apathy from depression in neurocognitive disorders
Brain rhythms, proteinopathy, and neurochemistry along the Alzheimer’s disease continuum
February 5, 2025
Food on the brain: Nutrition in Indigenous communities
December 10, 2024
Navigating risk-taking in the presence of anosognosia: Decision-making capacity challenges in Alzheimer’s disease
December 3, 2024






